Literature DB >> 15623436

The plasminogen-MMP system is more activated in the scar than in viable myocardium 3 months post-MI in the rat.

Roger Gaertner1, Marie-Paule Jacob, Fabrice Prunier, Eduardo Angles-Cano, Jean-Jacques Mercadier, Jean-Baptiste Michel.   

Abstract

Left ventricular (LV) remodeling following myocardial infarction (MI) is a complex process involving extracellular matrix degradation and fibrosis. While early remodeling is beneficial, chronic remodeling leads to decompensated heart failure (HF). We assessed the hypothesis that activation of the plasminogen-MMP system is involved in the remodeling of the infarct scar and compared it to the remaining viable myocardium. MI was induced by coronary artery ligature in 42 male Wistar rats. Three months following surgery, animals were divided into compensated (n=26) or decompensated (n=16) groups and compared to sham-operated rats (n=17). Scar and remaining viable LV myocardium (LVM) were separately analyzed for MMP-2, -7, -9, urokinase type and tissue type plasminogen activator (uPA and tPA) mRNA levels by RT-PCR. Their protein or activity levels, plus those of plasminogen/plasmin, tissue inhibitor of metalloproteinase-1, -2, -4 (TIMP-1, -2, -4) and plasminogen activator inhibitor-1 (PAI-1) were analyzed in tissue conditioned media by Western blot, ELISA and/or zymography. MMP and plasmin proteolytic activities were increased in the scar as compared to paired LVM thus indicating that activation of plasminogen and pro-MMPs is a key event in scar tissue remodeling. MMP and plasminogen activators (uPA, tPA) mRNAs were increased accordingly. Furthermore, inhibitors of the proteolytic enzymes, TIMP-1 and PAI-1 were increased in the scars from failing hearts and LVM thus suggesting a dynamic interplay between proteolysis and its inhibitors. This study shows a high degree of activation of the MMP-plasminogen system and the balance with their inhibitors in the infarcted myocardium, and suggests that this activation participates more to the remodeling of the scar tissue than to the remaining myocardium.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15623436     DOI: 10.1016/j.yjmcc.2004.10.017

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  10 in total

Review 1.  Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver.

Authors:  Hassan K Awada; Mintai P Hwang; Yadong Wang
Journal:  Biomaterials       Date:  2015-12-29       Impact factor: 12.479

2.  The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair: urokinase attenuates ventricular remodeling.

Authors:  Elina Minami; Chiara Castellani; Laura Malchodi; Jennifer Deem; Kate Bertko; Jessica Meznarich; Monja Dishmon; Charles E Murry; April Stempien-Otero
Journal:  J Mol Cell Cardiol       Date:  2010-04-07       Impact factor: 5.000

3.  ZAK induces MMP-2 activity via JNK/p38 signals and reduces MMP-9 activity by increasing TIMP-1/2 expression in H9c2 cardiomyoblast cells.

Authors:  Yi-Chang Cheng; Wei-Wen Kuo; Hsi-Chin Wu; Tung-Yuan Lai; Chun-Hsien Wu; Jin-Ming Hwang; Wen-Hong Wang; Fuu-Jen Tsai; Jaw-Ji Yang; Chih-Yang Huang; Chun-Hsien Chu
Journal:  Mol Cell Biochem       Date:  2009-01-28       Impact factor: 3.396

4.  "Hypoxia-induced down-regulation of microRNA-449a/b impairs control over targeted SERPINE1 (PAI-1) mRNA - a mechanism involved in SERPINE1 (PAI-1) overexpression".

Authors:  Michaela Muth; Katharina Theophile; Kais Hussein; Christoph Jacobi; Hans Kreipe; Oliver Bock
Journal:  J Transl Med       Date:  2010-04-01       Impact factor: 5.531

5.  Validation of the vitronectin knockout mouse as a model for studying myocardial infarction: Vitronectin appears to influence left ventricular remodelling following myocardial infarction.

Authors:  Gordon E Pate; Hubert P Walinski; Lubos Bohunek; Thomas J Podor
Journal:  Exp Clin Cardiol       Date:  2013

Review 6.  Renal studies provide an insight into cardiac extracellular matrix remodeling during health and disease.

Authors:  Alexandre Hertig; Taduri Gangadhar; Raghu Kalluri
Journal:  J Mol Cell Cardiol       Date:  2009-07-30       Impact factor: 5.000

Review 7.  Matrix metalloproteinases and myocardial infarction.

Authors:  Wannakorn Phatharajaree; Arintaya Phrommintikul; Nipon Chattipakorn
Journal:  Can J Cardiol       Date:  2007-07       Impact factor: 5.223

Review 8.  Biochemical insights into the role of matrix metalloproteinases in regeneration: challenges and recent developments.

Authors:  I H Bellayr; X Mu; Y Li
Journal:  Future Med Chem       Date:  2009-09       Impact factor: 3.808

9.  Urokinase plasminogen activator protects cardiac myocytes from oxidative damage and apoptosis via hOGG1 induction.

Authors:  Philipp J Hohensinner; Nikol Takacs; Christoph Kaun; Barbara Thaler; Konstantin A Krychtiuk; Stefan Pfaffenberger; Arezu Aliabadi; Andreas Zuckermann; Kurt Huber; Johann Wojta
Journal:  Apoptosis       Date:  2017-08       Impact factor: 4.677

10.  Microarray analysis reveals the role of matrix metalloproteinases in mouse experimental autoimmune myocarditis induced by cardiac myosin peptides.

Authors:  Qizhu Tang; Ji Huang; Haiyan Qian; Ran Xiong; Difei Shen; Hui Wu; Zhouyan Bian; Xiaohong Wei
Journal:  Cell Mol Biol Lett       Date:  2007-01-19       Impact factor: 5.787

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.